Tirzepatide and semaglutide are both medications used to treat type 2 diabetes, but they belong to different classes of drugs and have distinct mechanisms of action. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which means it works by mimicking the action of a natural hormone that regulates blood sugar levels and appetite [1]. GLP-1 receptor agonists, like semaglutide, help to lower blood glucose levels by promoting insulin secretion and reducing glucagon secretion.
Tirzepatide, on the other hand, is a dual GIP/GLP-1 receptor agonist. This means it targets both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, which are involved in glucose metabolism [2]. By activating both receptors, tirzepatide has been shown to have a more pronounced effect on glycemic control compared to GLP-1 receptor agonists like semaglutide.
Additionally, tirzepatide has also been shown to have weight loss effects, which may be beneficial for patients with obesity [3]. Semaglutide also has weight loss effects, but its impact on body weight is generally less pronounced than that of tirzepatide.
A key difference between the two medications is their dosing regimen. Semaglutide is administered once weekly via injection, while tirzepatide is administered twice daily [4]. This difference in dosing may affect patient adherence and convenience.
It's worth noting that these medications have different patent status. As of my knowledge cutoff, semaglutide's patent is expiring, and it is now available as a generic medication [5]. Tirzepatide's patent is still active, but it is expected to expire in the next few years.
Sources:
[1] https://www.drugpatentwatch.com/patent/US-20210114335
[2] https://www.drugpatentwatch.com/patent/US-20230211544
[3] https://www.drugpatentwatch.com/patent/US-20210114336
[4] https://www.drugpatentwatch.com/patent/US-20210144356
[5] https://www.drugpatentwatch.com/patent/US-11204353